Epoprostenol Therapy Decreases Elevated Circulating Levels of Monocyte Chemoattractant Protein-1 in Patients with Primary Pulmonary Hypertension

Circulation Journal

Volumn 68, Issue 3, 2004, Pages 227-231

  Hashimoto, Katsushi ^a   Nakamura, Kazufumi ^a   Fujio, Hideki ^a   Miyaji, Katsumasa ^a   Morita, Hiroshi ^a   Kusano, Kengo ^a   Date, Hiroshi ^a   Shimizu, Nobuyoshi ^a   Emori, Tetsuro ^a   Matsubara, Hiromi ^a   Ohe, Tohru ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Epoprostenol; Monocyte chemoattractant protein 1; Pulmonary hypertension

Indexed keywords

ANTICOAGULANT AGENT; DIGITALIS; DIURETIC AGENT; MONOCYTE CHEMOTACTIC PROTEIN 1; PROSTACYCLIN; WARFARIN;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART RIGHT ATRIUM PRESSURE; HEMODYNAMICS; HUMAN; HYPERTENSION; LUNG ARTERY PRESSURE; LUNG WEDGE PRESSURE; MALE; PULMONARY HYPERTENSION; THROMBOEMBOLISM; TREATMENT OUTCOME;

ADULT; ANTIHYPERTENSIVE AGENTS; BLOOD FLOW VELOCITY; EPOPROSTENOL; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MACROPHAGE INFLAMMATORY PROTEIN-1; MALE; PULMONARY ARTERY; VASCULAR RESISTANCE;

EID: 12144290664     PISSN: 13469843     EISSN: None     Source Type: Journal    
DOI: 10.1253/circj.68.227     Document Type: Article

References (31)

1. Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Primary pulmonary hypertension: A national prospective study. Ann Intern Med 1987; 107: 216-223.
2. D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Survival in patients with primary pulmonary hypertension: Results from a national prospective registry. Ann Intern Med 1991; 115: 343-349.
3. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: The impact of epoprostenol therapy. Circulation 2002; 106: 1477-1482.
4. Archer S, Rich S. Primary pulmonary hypertension: A vascular biology and translational research 'Work in progress'. Circulation 2000; 102: 2781-2791.
5. Tuder RM, Groves B, Badesch DB, Voelkel NF. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol 1994; 144: 275-285.
6. Heath D. The pathology of pulmonary hypertension Eur Respir Rev 31: 555-558.
7. Rollins BJ. Chemokines. Blood 1997; 90: 909-928.
8. Luster AD. Chemokines: Chemotactic cytokines that mediate inflammation. N Engl J Med 1998; 338: 436-445.
9. Porreca E, Di Febbo C, Reale M, Castellani ML, Baccante G, Barbacane R, et al. Monocyte chemotactic protein 1 (MCP-1) is a mitogen for cultured rat vascular smooth muscle cells. J Vasc Res 1997; 34: 58-65.
10. Denger S, Jahn L, Wende P, Watson L, Gerber SH, Kubler W, et al. Expression of monocyte chemoattractant protein-1 cDNA in vascular smooth muscle cells: Induction of the synthetic phenotype: A possible clue to SMC differentiation in the process of atherogenesis. Atherosclerosis 1999; 144: 15-23.
11. Weber KS, Nelson PJ, Grone HJ, Weber C. Expression of CCR2 by endothelial cells: Implications for MCP-1 mediated wound injury repair and in vivo inflammatory activation of endothelium. Arterioscler Thromb Vasc Biol 1999; 19: 2085-2093.
12. Yla-Herttuala S, Lipton BA, Rosenfeld ME, Sarkioja T, Yoshimura T, Leonard EJ, et al. Expression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic lesions. Proc Natl Acad Sci USA 1991; 88: 5252-5256.
13. Egashira K. Molecular mechanisms mediating inflammation in vascular disease: Special reference to monocyte chemoattractant protein-1. Hypertension 2003; 41: 834-841.
14. Egashira K. Clinical importance of endothelial function in arteriosclerosis and ischemic heart disease. Circ J 2002; 66: 529-533.
15. Kitamoto S, Egashira K, Takeshita A. Stress and vascular responses: Anti-inflammatory therapeutic strategy against atherosclerosis and restenosis after coronary intervention. J Pharmacol Sci 2003; 91: 192-196.
16. Furukawa Y, Matsumori A, Ohashi N, Shioi T, Ono K, Harada A, et al. Anti-monocyte chemoattractant protein-1/monocyte chemotactic and activating factor antibody inhibits neointimal hyperplasia in injured rat carotid arteries. Circ Res 1999; 84: 306-314.
17. Hokimoto S, Ogawa H, Saito T, Oshima S, Noda K, Soejima H, et al. Increased plasma antigen levels of monocyte chemoattractant protein-1 in patients with restenosis after percutaneous transluminal coronary angioplasty. Jpn Circ J 2000; 64: 831-834.
18. Hokimoto S, Oike Y, Saito T, Kitaoka M, Oshima S, Noda K, et al. Increased expression of monocyte chemoattractant protein-1 in atherectomy specimens from patients with restenosis after percutaneous transluminal coronary angioplasty. Circ J 2002; 66: 114-116.
19. Kimura H, Kasahara Y, Kurosu K, Sugito K, Takiguchi Y, Terai M, et al. Alleviation of monocrotaline-induced pulmonary hypertension by antibodies to monocyte chemotactic and activating factor/monocyte chemoattractant protein-1. Lab Invest 1998; 78: 571-581.
20. Ikeda Y, Yonemitsu Y, Kataoka C, Kitamoto S, Yamaoka T, Nishida K, et al. Anti-monocyte chemoattractant protein-1 gene therapy attenuates pulmonary hypertension in rats. Am J Physiol Heart Circ Physiol 2002; 283: H2021-H2028.
21. Rollins BJ, Yoshimura T, Leonard EJ, Pober JS. Cytokine-activated human endothelial cells synthesize and secrete a monocyte chemoattractant, MCP-1/JE. Am J Pathol 1990; 136: 1229-1233.
22. Sica A, Wang JM, Colotta F, Dejana E, Mantovani A, Oppenheim JJ, et al. Monocyte chemotactic and activating factor gene expression induced in endothelial cells by IL-1 and tumor necrosis factor. J Immunol 1990; 144: 3034-3038.
23. Humbert M, Monti G, Brenot F, Sitbon O, Portier A, Grangeot-Keros L, et al. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med 1995; 151: 1628-1631.
24. Kakishita M, Nishikimi T, Okano Y, Satoh T, Kyotani S, Nagaya N, et al. Increased plasma levels of adrenomedullin in patients with pulmonary hypertension. Clin Sci (Lond) 1999; 96: 33-39.
25. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension: The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 334: 296-302.
26. Shapiro SM, Oudiz RJ, Cao T, Romano MA, Beckmann XJ, Georgiou D, et al. Primary pulmonary hypertension: Improved long-term effects and survival with continuous intravenous epoprostenol infusion. J Am Coll Cardiol 1997; 30: 343-349.
27. McLaughlin VV, Genthner DE, Panella MM, Rich S. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 1998; 338: 273-277.
28. Magnani B, Galie N. Prostacyclin in primary pulmonary hypertension. Eur Heart J 1996; 17: 18-24.
29. Luttmann W, Herzog V, Matthys H, Thierauch KH, Virchow JC, Kroegel C. Modulation of cytokine release from mononuclear cells by prostacyclin, IL-4 and IL-13. Cytokine 1999; 11: 127-133.
30. Meja KK, Barnes PJ, Giembycz MA. Characterization of the prostanoid receptor(s) on human blood monocytes at which prostaglandin E2 inhibits lipopolysaccharide-induced tumour necrosis factor-alpha generation. Br J Pharmacol 1997; 122: 149-157.
31. Raychaudhuri B, Malur A, Bonfield TL, Abraham S, Schilz RJ, Farver CF, et al. The prostacyclin analogue treprostinil blocks NFkappaB nuclear translocation in human alveolar macrophages. J Biol Chem 2002; 277: 33344-33348.